Khosla Rachna 4

4 · AMGEN INC · Filed May 7, 2026

AI-generated summary of this filing

Updated May 8, 2026

Amgen SVP Rachna Khosla Receives Awards Worth ~$1.08M

What Happened

Rachna Khosla, Senior Vice President, Business Development at Amgen (AMGN), was awarded equity on 2026-05-05: a grant listed as 500 shares (acquired) and a derivative award of 3,266 units valued at $329.59 each (total ≈ $1,076,441). On 2026-05-06, 79 shares were surrendered/withheld to cover tax withholding obligations, valued at $329.59 each (≈ $26,038).
The awards are grants (not open-market purchases or sales). The 79-share disposition is a routine tax-withholding event, not a directional sale.

Key Details

Transaction dates and prices: awards on 2026-05-05; tax-withholding disposition on 2026-05-06 at $329.59/share.
Reported values: derivative award ≈ $1,076,441; tax withholding ≈ $26,038.
Shares owned after the transactions: not specified in the provided filing excerpt.
Footnotes of note:
- F1: The RSUs were granted under Amgen’s Equity Incentive Plan and vest in four equal annual installments (25% per year) beginning 5/5/2027; vested RSUs convert to common shares 1:1.
- F2: The awards include 69 Dividend Equivalents (credited to unvested RSUs and paid in shares per vesting).
- F3: Non-qualified stock options were granted and vest/exercise in four equal annual installments beginning 5/5/2027.
Filing timeliness: filed 2026-05-07 for transactions on 5/5 and 5/6; no late filing indicated.

Context

The 79-share disposition was to satisfy tax withholding (common when RSUs vest or when awards are settled) — not an open-market sale signaling a change in view.
The main takeaway for investors: this is an equity compensation grant to a senior executive (worth roughly $1.08M on grant date) with standard multi-year vesting; purchases or sales that indicate personal conviction were not reported.

Form 4

Period: 2026-05-05

SVP, Business Development

Transactions

Award
Common Stock
[F1]
2026-05-05+500→ 8,566 total
Tax Payment
Common Stock
[F2]
2026-05-06$329.59/sh−79$26,038→ 8,487 total
Award
Nqso (Right to Buy)
[F3]
2026-05-05$329.59/sh+3,266$1,076,441→ 3,266 total
Exercise: $329.59From: 2027-05-05Exp: 2036-05-05→ Common Stock (3,266 underlying)

Footnotes (3)

[F1]The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
[F2]These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
[F3]These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.

Signature

/s/ Rachna Khosla|2026-05-06

1 file